Cargando…

Naturally occurring compounds as pancreatic cancer therapeutics

Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit f...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohse, Ines, Wildermuth, Erin, Brothers, Shaun P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226042/
https://www.ncbi.nlm.nih.gov/pubmed/30459936
http://dx.doi.org/10.18632/oncotarget.26234
_version_ 1783369890039595008
author Lohse, Ines
Wildermuth, Erin
Brothers, Shaun P.
author_facet Lohse, Ines
Wildermuth, Erin
Brothers, Shaun P.
author_sort Lohse, Ines
collection PubMed
description Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.
format Online
Article
Text
id pubmed-6226042
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-62260422018-11-20 Naturally occurring compounds as pancreatic cancer therapeutics Lohse, Ines Wildermuth, Erin Brothers, Shaun P. Oncotarget Review Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds. Impact Journals LLC 2018-10-23 /pmc/articles/PMC6226042/ /pubmed/30459936 http://dx.doi.org/10.18632/oncotarget.26234 Text en Copyright: © 2018 Lohse et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Lohse, Ines
Wildermuth, Erin
Brothers, Shaun P.
Naturally occurring compounds as pancreatic cancer therapeutics
title Naturally occurring compounds as pancreatic cancer therapeutics
title_full Naturally occurring compounds as pancreatic cancer therapeutics
title_fullStr Naturally occurring compounds as pancreatic cancer therapeutics
title_full_unstemmed Naturally occurring compounds as pancreatic cancer therapeutics
title_short Naturally occurring compounds as pancreatic cancer therapeutics
title_sort naturally occurring compounds as pancreatic cancer therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226042/
https://www.ncbi.nlm.nih.gov/pubmed/30459936
http://dx.doi.org/10.18632/oncotarget.26234
work_keys_str_mv AT lohseines naturallyoccurringcompoundsaspancreaticcancertherapeutics
AT wildermutherin naturallyoccurringcompoundsaspancreaticcancertherapeutics
AT brothersshaunp naturallyoccurringcompoundsaspancreaticcancertherapeutics